# Amgen Type: Company Source: GetYourBrief — https://getyourbrief.com/entity/amgen Canonical HTML page: https://getyourbrief.com/entity/amgen ## Timeline - **2026-08-06**: SpaceX Post-IPO Lock-Up Expiry Begins — The expiration of the lock-up period for SpaceX’s recently public shares is expected to increase potential selling pressure. - **2026-08-05**: Dow Clinches New Record; Tech Slumps — The Dow rose 0.49% to 54,349.06. The S&P 500 dipped 0.17%. The Nasdaq fell 0.83% as SpaceX and AMD shares tumbled after earnings. Amgen and Disney led the Dow. - **2026-08-04**: Dow and S&P 500 Set Records — Both indexes closed at all-time highs on Tuesday as oil prices and U.S. Treasury yields dropped on hopes of a Middle East peace deal, easing inflation and rate-hike fears. - **2026-07-16**: FDA Approves Lipfendra — The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction. - **2026-07-16**: FDA approves Merck's Lipfendra — The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients. - **2026-05**: Marty Makary resigns as FDA Commissioner — Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure. - **2026-03-08**: Q4 2025 Preview — Analysts set expectations for oncology-driven revenue growth. - **2025-01-01**: Loqtorzi Launch — Full commercial ramp-up of the first-in-class PD-1 for NPC. - **2024-06-01**: Yusimry Divestiture — Sale of adalimumab biosimilar to HK King-Friend for $40M. - **2024-01-01**: Cimerli Divestiture — Coherus sells its ranibizumab biosimilar to Sandoz for $170M. ## Recent coverage (14 stories, network-wide) ### Dow Hits 54,349 Record as Mideast Hopes Lift Industrials, Nasdaq Slips 0.8% 2026-08-06 00:26:52 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3 The Dow Jones Industrial Average closed at a record 54,349.06 on August 5, buoyed by a potential Iran-Oman peace deal that eased rate-hike fears. In contrast, the Nasdaq fell 0.8% as SpaceX’s 13.6% post-earnings plunge and an AMD drop underscored mounting skepticism about sustained AI spending. Full story: https://getfinancebrief.com/story/dow-record-54349-mideast-optimism-nasdaq-slips ### Oscar Health Stock Under Scrutiny as Copay Accumulator Shifts $7,600 Cost to Patient 2026-07-27 11:00:41 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Oscar Health's use of a copay accumulator program has drawn attention to how insurers manage medical loss ratios. By not counting manufacturer assistance, insurers keep claims low, but regulatory and reputational risks could affect investor outlook. Full story: https://getfinancebrief.com/story/copay-accumulator-insurer-financial-impact ### Insurer Pocketed $7,700/Month Drug Coupon, Forcing Patient to Pay $10,600 2026-07-27 11:00:04 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Copay accumulator programs are shifting thousands in drug costs back to patients, causing financial distress and potential treatment delays. Larry Gruber’s experience with Oscar Health highlights the human toll of insurance practices that prioritize cost over care. Full story: https://gethealthbrief.com/story/copay-accumulator-patient-impact ### Amgen's Enbrel Copay Assistance Nullified: Insurer Seizes $7,700/Month Coupon 2026-07-27 10:59:55 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4 Drugmaker copay assistance programs are meant to lower barriers to high-cost specialty drugs, but accumulator programs circumvent them. For Amgen and other pharma companies, this practice threatens patient adherence and undermines the value of patient support initiatives. Full story: https://getbiobrief.com/story/copay-accumulator-pharma-strategy ### Merck's Lipfendra: 59% LDL Cut with First Oral PCSK9 Pill Approved 2026-07-16 23:20:10 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 7 The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol. Full story: https://gethealthbrief.com/story/merck-lipfendra-oral-pcsk9-pill-59-percent-ldl-cut-health-systems ### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions 2026-07-16 22:00:46 · Sector: health · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132 The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol. Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access ### Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals 2026-07-16 22:00:10 · Sector: bio · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132 Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron. Full story: https://getbiobrief.com/story/merck-lipfendra-fda-approval-oral-pcsk9-59-percent ### NovoCure’s $655M Revenue Signals a Shift in Direct-to-Patient Cancer Care 2026-06-28 04:07:26 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics. Full story: https://gethealthbrief.com/story/novocure-direct-patient-model-healthcare-2026 ### Amgen’s $36.8B Pipeline vs NovoCure’s Tumor-Fighting Tech: Which Innovator Wins? 2026-06-28 04:07:18 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors. Full story: https://getbiobrief.com/story/amgen-vs-novocure-biopharma-innovation-2026 ### Hong Kong Attracts $191.5B Amgen for Health Tech Boost 2026-04-21 02:09:05 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Hong Kong's enterprise scheme is drawing major health firms like Amgen and Pfizer, valued at over $191.5 billion combined, to expand operations and drive innovation in biotechnology. This influx could enhance local health IT infrastructure and research capabilities, while also raising questions about regulatory alignment with global health standards. For healthcare professionals, this represents opportunities in clinical advancements and talent development amid increasing regional competition. Full story: https://gethealthbrief.com/story/hong-kong-health-scheme-impact ### Coherus BioSciences Q4 2025 Preview: Oncology Pivot and Udenyca Onbody Growth 2026-03-08 22:54:39 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Coherus BioSciences is set to report Q4 2025 earnings as it completes its strategic transition into a pure-play oncology firm. Investors are focused on the commercial ramp of Loqtorzi and the market share recovery of the Udenyca franchise following the launch of its Onbody injector. Full story: https://getbiobrief.com/story/coherus-biosciences-q4-2025-earnings-preview-oncology-strategy ### Coherus BioSciences Q4 Preview: Oncology Pivot and Udenyca Growth in Focus 2026-03-08 22:51:31 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures. Full story: https://gethealthbrief.com/story/coherus-biosciences-q4-2025-earnings-preview-oncology-pivot ### Statin Dominance Challenged by Growing Patient Advocacy for Treatment Choice 2026-02-22 11:01:18 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 10 A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters. Full story: https://getbiobrief.com/story/statin-controversy-heart-disease-treatment-choice ### Breaking the Silence: The Shift Toward Shared Decision-Making in Statin Therapy 2026-02-22 10:28:01 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3 A growing movement in cardiovascular care is challenging the 'prescribe-first' mentality of statin therapy, emphasizing patient autonomy and shared decision-making. As clinical guidelines evolve, the healthcare industry is grappling with how to balance standardized protocols with individualized patient preferences and risk profiles. Full story: https://gethealthbrief.com/story/statin-therapy-shared-decision-making-trends --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.